# US 2025/0144067 A1 · Personalized starvation therapy for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144067 A1
- Document ID: US20250144067A1
- Status: Published application
- Kind: A1
- Application number: 18/676,700
- Filed: 2024-05-29
- Published: 2025-05-08
- Earliest claimed: 2021-12-10
- Assignees: Faeth Therapeutics, Inc.
- Applicants: Faeth Therapeutics, Inc.
- Inventors: Oliver D.K. MADDOCKS; Swati MISHRA
- Web page: https://patentgrep.com/patent/US20250144067A1

## CPC

- A61K 31/351: not condensed with another ring
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of administering an inhibitor of the mevalonate pathway with a diet low in cholesterol or lipids. The methods of the present invention can be used to treat conditions such as cancer.

## Claims

### Claim 1

A method of treating a cancer in a subject in need thereof, the method comprising:
a) administering to the subject a therapeutically effective amount of an inhibitor of a mevalonate pathway; and
b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids.

### Claim 2 (depends on 1)

The method of claim 1, wherein the diet comprises less than about 200 mg/day of cholesterol.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitor of the mevalonate pathway is an HMG-CoA reductase inhibitor.

### Claim 4 (depends on 3)

The method of claim 3, wherein the diet comprises less than about 200 mg/day of cholesterol.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer, pancreatic cancer, head and neck cancer, colorectal cancer, renal cancer, breast cancer, a blood cancer, or liver cancer.

### Claim at position 8

8-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the inhibitor of the mevalonate pathway is a statin.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The method of claim 16, wherein the statin is atorvastatin or a pharmaceutically acceptable salt thereof, fluvastatin or a pharmaceutically acceptable salt thereof, pravastatin or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof, simvastatin or a pharmaceutically acceptable salt thereof, pitavastatin or a pharmaceutically acceptable salt thereof, or lovastatin or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the statin is atorvastatin calcium, fluvastatin sodium, pravastatin sodium, rosuvastatin calcium, simvastatin sodium, pitavastatin calcium, pitavastatin magnesium, or lovastatin sodium.

### Claim 20 (depends on 18)

The method of claim 18, wherein the therapeutically effective amount of the atorvastatin or the pharmaceutically acceptable salt is from about 10 mg/day to about 80 mg/day, the therapeutically effective amount of the fluvastatin or the pharmaceutically acceptable salt is from about 10 mg/day to about 80 mg/day, the therapeutically effective amount of the pravastatin or the pharmaceutically acceptable salt is from about 20 mg/day to about 60 mg/day, the therapeutically effective amount of the rosuvastatin or the pharmaceutically acceptable salt is from about 5 mg/day to about 40 mg/day, the therapeutically effective amount of the simvastatin or the pharmaceutically acceptable salt is from about 5 mg/day to about 40 mg/day, the therapeutically effective amount of the pitavastatin or the pharmaceutically acceptable salt is from about 1.5 mg/day to about 4.5 mg/day, or the therapeutically effective amount of the lovastatin or the pharmaceutically acceptable salt is from about 1 mg/day to about 5 mg/day.

### Claim at position 14

21-39. (canceled)

### Claim 40 (depends on 1)

The method of claim 1, further comprising administering a therapeutically-effective amount of a cholesterol lowering agent.

### Claim at position 16

41-43. (canceled)

### Claim 44 (depends on 1)

The method of claim 1, further comprising administering a cancer therapy.

### Claim 45 (depends on 44)

The method of claim 44, wherein the cancer therapy is a chemotherapeutic agent.

### Claim 46 (depends on 44)

The method of claim 44, wherein the cancer therapy is radiotherapy.

### Claim 47 (depends on 44)

The method of claim 44, wherein the cancer therapy is an immunotherapy.

### Claim 48 (depends on 1)

The method of claim 1, wherein the diet is a vegan diet, a vegetarian diet, a plant based diet, or a diet devoid of animal fats.

### Claim at position 22

49-91. (canceled)

### Claim 92 (depends on 40)

The method of claim 40, wherein the cholesterol lowering agent is a cholesteryl ester transfer protein (CETP) inhibitor, a lecithin-cholesterol acyltransferase (LCAT) inhibitor, a bile acid sequestrant, or a cholesterol absorption inhibitor.

### Claim at position 24

93-122.

### Claim 123 (depends on 1)

The method of claim 1, wherein the diet comprises less than 15% of total kcal/day in saturated fats.

### Claim 124 (depends on 1)

The method of claim 1, wherein the diet comprises less than 5% of total kcal/day in trans fats.

### Claim 125 (depends on 1)

The method of claim 1, wherein the diet comprises less than 15% of total kcal/day in polyunsaturated fats.

### Claim 126 (depends on 1)

The method of claim 1, wherein the diet comprises less than 5% of total kcal/day in monounsaturated fats.

### Claim 127 (depends on 1)

The method of claim 1, wherein the diet comprises less than 20 g/day a daily recommended intake value of saturated fat.

### Claim 128

(canceled)

### Claim 129 (depends on 1)

The method of claim 1, wherein the subject consumes a 2000 kcal/day diet.
